Fmr llc sells Beam therapeutics (BEAM) shares for $991667

Published 01/08/2025, 14:44
Fmr llc sells Beam therapeutics (BEAM) shares for $991667

FMR LLC, a ten percent owner of Beam Therapeutics Inc . (NASDAQ:BEAM), sold 48,374 shares of common stock on July 30, 2025, at a price of $20.50, according to a Form 4 filing with the Securities and Exchange Commission. The total value of the transaction amounted to $991,667. The sale price represents a premium to the current trading price of $19.30, with the stock down nearly 35% over the past year. According to InvestingPro analysis, BEAM appears slightly undervalued based on its Fair Value assessment.

Following the transaction, FMR LLC continues to own 2,073,665 shares held by persons and entities whose shares are subject to reporting by the undersigned, 1,139,443 shares held by F-Prime Capital Partners (WA:CPAP) Healthcare Fund V LP and 473 shares held by FMR Capital, Inc. With a market capitalization of $1.88 billion and an overall Financial Health score rated as "FAIR" by InvestingPro, investors can access comprehensive analysis including 12+ key financial metrics and detailed Pro Research Reports available exclusively for subscribers.

In other recent news, Beam Therapeutics Inc. has reported positive data from its BEACON Phase 1/2 clinical trial of BEAM-101, a base-editing therapy for sickle cell disease (SCD). The trial data from 17 patients showed significant improvements, with hemoglobin F levels exceeding 60% and sickle hemoglobin levels dropping below 40%. Additionally, Beam Therapeutics’ BEAM-101 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA), which aims to facilitate the development of treatments for rare diseases like SCD. In another development, the company received FDA orphan drug status for BEAM-302, its investigational treatment for alpha-1 antitrypsin deficiency (AATD). This designation offers benefits such as tax credits and potential market exclusivity upon approval. H.C. Wainwright has reiterated its Buy rating on Beam Therapeutics, with an $80 target price, highlighting the company’s innovative technology and promising trial results. These recent developments indicate ongoing advancements in Beam’s therapeutic pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.